PCSK9 and metabolic dysfunction-associated steatotic liver disease: PCSK9 inhibition models observed an increase in hepatic TG both in cellular and animal models, indicating that a rise in hepatic levels of CD36 could increase NAFLD susceptibility.109,185 Recently, Ioannou and colleagues also confirmed this finding in their experiments, showing that PCSK9 deletion exacerbated murine NASH.